vs
Side-by-side financial comparison of Cencora (COR) and Home Depot (The) (HD). Click either name above to swap in a different company.
Cencora is the larger business by last-quarter revenue ($78.4B vs $39.7B, roughly 2.0× Home Depot (The)). Home Depot (The) runs the higher net margin — 7.5% vs 2.1%, a 5.5% gap on every dollar of revenue. On growth, Home Depot (The) posted the faster year-over-year revenue change (3.9% vs 3.8%). Over the past eight quarters, Home Depot (The)'s revenue compounded faster (4.4% CAGR vs -0.4%).
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment.
Home Depot (The)HDEarnings & Financial Report
The Home Depot, Inc., often referred to as Home Depot, is an American multinational home improvement retail corporation which sells tools, construction products, appliances, and services including fuel and transportation rentals. Home Depot is the largest home improvement retailer in the United States. In 2021, the company had 490,600 employees and more than $151 billion in revenue. The company is headquartered in Cobb County, Georgia, with an Atlanta mailing address.
COR vs HD — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $78.4B | $39.7B |
| Net Profit | $1.6B | $3.0B |
| Gross Margin | 4.6% | 32.8% |
| Operating Margin | 1.5% | 11.3% |
| Net Margin | 2.1% | 7.5% |
| Revenue YoY | 3.8% | 3.9% |
| Net Profit YoY | 2.1% | 16.6% |
| EPS (diluted) | $8.40 | $3.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $78.4B | — | ||
| Q1 26 | $85.9B | — | ||
| Q4 25 | $85.9B | $41.4B | ||
| Q3 25 | $83.7B | $45.3B | ||
| Q2 25 | $80.7B | $39.9B | ||
| Q1 25 | $75.5B | $39.7B | ||
| Q4 24 | $81.5B | $40.2B | ||
| Q3 24 | $79.1B | $43.2B |
| Q2 26 | $1.6B | — | ||
| Q1 26 | $566.1M | — | ||
| Q4 25 | $559.6M | $3.6B | ||
| Q3 25 | $-339.7M | $4.6B | ||
| Q2 25 | $687.4M | $3.4B | ||
| Q1 25 | $717.9M | $3.0B | ||
| Q4 24 | $488.6M | $3.6B | ||
| Q3 24 | $3.4M | $4.6B |
| Q2 26 | 4.6% | — | ||
| Q1 26 | 3.6% | — | ||
| Q4 25 | 3.6% | 33.4% | ||
| Q3 25 | 3.5% | 33.4% | ||
| Q2 25 | 3.6% | 33.8% | ||
| Q1 25 | 4.1% | 32.8% | ||
| Q4 24 | 3.1% | 33.4% | ||
| Q3 24 | 3.2% | 33.4% |
| Q2 26 | 1.5% | — | ||
| Q1 26 | 0.9% | — | ||
| Q4 25 | 0.9% | 12.9% | ||
| Q3 25 | 0.0% | 14.5% | ||
| Q2 25 | 1.1% | 12.9% | ||
| Q1 25 | 1.4% | 11.3% | ||
| Q4 24 | 0.9% | 13.5% | ||
| Q3 24 | 0.2% | 15.1% |
| Q2 26 | 2.1% | — | ||
| Q1 26 | 0.7% | — | ||
| Q4 25 | 0.7% | 8.7% | ||
| Q3 25 | -0.4% | 10.1% | ||
| Q2 25 | 0.9% | 8.6% | ||
| Q1 25 | 1.0% | 7.5% | ||
| Q4 24 | 0.6% | 9.1% | ||
| Q3 24 | 0.0% | 10.6% |
| Q2 26 | $8.40 | — | ||
| Q1 26 | $2.87 | — | ||
| Q4 25 | $2.87 | $3.62 | ||
| Q3 25 | $-1.74 | $4.58 | ||
| Q2 25 | $3.52 | $3.45 | ||
| Q1 25 | $3.68 | $3.01 | ||
| Q4 24 | $2.50 | $3.67 | ||
| Q3 24 | $0.04 | $4.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.2B | $1.7B |
| Total DebtLower is stronger | $12.4B | $316.0M |
| Stockholders' EquityBook value | $3.6B | $6.6B |
| Total Assets | $81.7B | $96.1B |
| Debt / EquityLower = less leverage | 3.45× | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $2.2B | — | ||
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $1.7B | ||
| Q3 25 | $4.4B | $2.8B | ||
| Q2 25 | $2.2B | $1.4B | ||
| Q1 25 | $2.0B | $1.7B | ||
| Q4 24 | $3.2B | $1.5B | ||
| Q3 24 | $3.1B | $1.6B |
| Q2 26 | $12.4B | — | ||
| Q1 26 | $7.9B | — | ||
| Q4 25 | $7.9B | $46.3B | ||
| Q3 25 | $7.7B | $45.9B | ||
| Q2 25 | $8.2B | $47.3B | ||
| Q1 25 | $7.9B | $48.5B | ||
| Q4 24 | $8.1B | $50.1B | ||
| Q3 24 | $4.4B | $51.9B |
| Q2 26 | $3.6B | — | ||
| Q1 26 | $2.1B | — | ||
| Q4 25 | $1.9B | $12.1B | ||
| Q3 25 | $1.5B | $10.7B | ||
| Q2 25 | $2.0B | $8.0B | ||
| Q1 25 | $1.0B | $6.6B | ||
| Q4 24 | $226.6M | $5.8B | ||
| Q3 24 | $645.9M | $4.4B |
| Q2 26 | $81.7B | — | ||
| Q1 26 | $78.4B | — | ||
| Q4 25 | $78.4B | $106.3B | ||
| Q3 25 | $76.6B | $100.0B | ||
| Q2 25 | $74.0B | $99.2B | ||
| Q1 25 | $71.2B | $96.1B | ||
| Q4 24 | $69.1B | $97.3B | ||
| Q3 24 | $67.1B | $96.8B |
| Q2 26 | 3.45× | — | ||
| Q1 26 | 3.78× | — | ||
| Q4 25 | 4.15× | 3.82× | ||
| Q3 25 | 5.08× | 4.31× | ||
| Q2 25 | 4.16× | 5.95× | ||
| Q1 25 | 7.76× | 7.30× | ||
| Q4 24 | 35.96× | 8.65× | ||
| Q3 24 | 6.79× | 11.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $19.8B |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.4% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 6.61× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | $527.9M | — | ||
| Q4 25 | $-2.3B | $4.0B | ||
| Q3 25 | $3.1B | $4.6B | ||
| Q2 25 | $109.2M | $4.3B | ||
| Q1 25 | $3.4B | $4.7B | ||
| Q4 24 | $-2.7B | $4.2B | ||
| Q3 24 | $1.0B | $5.4B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-2.4B | $3.1B | ||
| Q3 25 | $2.9B | $3.7B | ||
| Q2 25 | $-74.0M | $3.5B | ||
| Q1 25 | $3.2B | $3.6B | ||
| Q4 24 | $-2.8B | $3.4B | ||
| Q3 24 | $818.1M | $4.7B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -2.8% | 7.5% | ||
| Q3 25 | 3.4% | 8.2% | ||
| Q2 25 | -0.1% | 8.8% | ||
| Q1 25 | 4.3% | 9.0% | ||
| Q4 24 | -3.5% | 8.5% | ||
| Q3 24 | 1.0% | 10.9% |
| Q2 26 | 0.4% | — | ||
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.1% | 2.2% | ||
| Q3 25 | 0.3% | 2.0% | ||
| Q2 25 | 0.2% | 2.0% | ||
| Q1 25 | 0.2% | 2.8% | ||
| Q4 24 | 0.1% | 2.0% | ||
| Q3 24 | 0.2% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | 0.93× | — | ||
| Q4 25 | -4.12× | 1.11× | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | 0.16× | 1.26× | ||
| Q1 25 | 4.67× | 1.56× | ||
| Q4 24 | -5.56× | 1.16× | ||
| Q3 24 | 295.80× | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COR
| U.S. Healthcare Solutions | $68.8B | 88% |
| International Healthcare Solutions | $7.6B | 10% |
| Other | $2.0B | 3% |
HD
Segment breakdown not available.
